FGL-L (FGL Peptide)

FGL (EVYVVAENQQGKSKA) is a 15-amino-acid peptide corresponding to the FG loop (fibroblast growth factor loop) region of the second fibronectin type III (F3II) module of neural cell adhesion molecule (NCAM). NCAM is a transmembrane glycoprotein that mediates cell-cell adhesion and signaling during neural development, synaptic plasticity, and learning. The FG loop is a specific structural motif within NCAM's extracellular domain that directly interacts with and activates fibroblast growth factor receptor 1 (FGFR1) — a receptor tyrosine kinase normally activated by FGF ligands.

What makes FGL mechanistically unique is that it directly activates FGFR1 independently of FGF ligands. When FGL binds FGFR1, it triggers the same downstream signaling cascades as native FGF-FGFR1 binding: PLCγ → PKC → calcium mobilization (synaptic vesicle release), and MAPK/ERK → CREB phosphorylation (gene transcription for synaptic plasticity). In primary hippocampal neuron cultures, FGL treatment produced a dramatic increase in synaptogenesis — the formation of new functional synapses — measured by increases in synaptophysin puncta and enhanced presynaptic function. Unlike neurotrophin-based approaches (BDNF/NGF), FGL's mechanism is anchored in cell adhesion biology rather than growth factor signaling, making it a genuinely orthogonal approach to cognitive enhancement.

Behavioral studies have demonstrated that FGL administration facilitates both memory acquisition and memory consolidation in rodent models — effects attributed to the peptide's ability to lower the threshold for activity-dependent synaptic strengthening. The peptide appears to enhance the brain's natural capacity for synapse formation and remodeling rather than forcing a fixed pattern of synaptic change, which may explain why its effects are most pronounced in learning-dependent rather than resting-state neural circuits.

FGL was developed in the early 2000s at the University of Copenhagen by a team led by Vladimir Berezin and Elisabeth Bock, who had been systematically mapping the structure-function relationships of NCAM's extracellular domains. Their work identified the F3II module's FG loop as the critical interface for NCAM-FGFR1 signaling, and they demonstrated that a synthetic peptide corresponding to this loop could recapitulate NCAM's synaptogenic effects in isolation. The seminal paper was published in the Journal of Neuroscience in 2004 (Cambon et al., J Neurosci 24:4197).

Subsequent research expanded the profile: rodent studies demonstrated enhanced spatial memory, improved social recognition, and facilitated fear-extinction learning. A 2012 study in an Alzheimer's disease mouse model reported that FGL treatment rescued cognitive deficits and reduced amyloid-beta pathology, sparking interest in the peptide as a disease-modifying cognitive therapeutic. However, the NCAM field contracted in the 2010s as funding priorities shifted toward amyloid and tau immunotherapies for Alzheimer's, and FGL has not progressed to human clinical trials. It remains a mechanistically well-characterized research tool for studying NCAM-FGFR1 synaptogenic signaling with an unusually strong connection between its structural biology and cognitive effects.

Store lyophilized FGL at -20°C in a light-protected, desiccated container. The 15-amino-acid peptide contains no cysteine residues and no disulfide bonds, simplifying its structure but potentially reducing long-term stability compared to disulfide-stabilized peptides. The peptide is water-soluble and forms a clear, colorless solution upon reconstitution. Stability under optimal conditions is expected to exceed 18 months.

After reconstitution, FGL should be stored at 2–8°C and used within 21 days. For intranasal protocols using sterile saline (rather than BAC water), use within 14 days — the absence of benzyl alcohol preservative reduces the microbiological stability of the solution. The intranasal route is the primary research administration route and achieves rapid CNS penetration while largely avoiding first-pass metabolism. Do not freeze reconstituted FGL solutions.